Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 2Active not recruiting 2Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Burkitt Lymphoma 1

Interventions

pembrolizumab 245Nivolumab 141Cisplatin 137Cyclophosphamide 134Paclitaxel 115Carboplatin 108Gemcitabine 98Radiotherapy 84Dexamethasone 83Docetaxel 77atezolizumab 69Ipilimumab 67Fluorouracil 61Doxorubicin 61Blood Specimen Collection 59Bevacizumab 59Rituximab 55fludarabine 54Etoposide 53Oxaliplatin 52Lenalidomide 50Surveys and Questionnaires 49Prednisone 47Standard of Care 45Magnetic Resonance Spectroscopy 45Radiosurgery 44Cetuximab 44lenvatinib 43Capecitabine 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × hydrocortisone hemisuccinate × 1 year × Clear all
NCT02883049 2026-06-02

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

National Cancer Institute (NCI)

Phase 3 Completed
5,949 enrolled 28 charts
Lymphoid

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡